Novo Nordisk receives FDA approval for weekly growth hormone treatment for children with Turner syndrome
NVO Novo Nordisk ADR
$37.82 -2.70%
View chart & analysis → - 1Novo Nordisk has received FDA approval for Sogroya for children with Turner syndrome.
- 2Sogroya recorded an average annual growth rate of 8.9cm in the weekly Sogroya administration group over 52 weeks.
- 3This treatment provides 313 days per year without requiring an injection.
So what's the key point?
Novo Nordisk received approval for a weekly growth hormone treatment for children with Turner syndrome. This medicine helps patients because they do not need to receive an injection for 313 days out of the year.
Source Nasdaq +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.